Concepedia

Markus F. Scheerer

MF

Statistics

Publications

34

Citations

1.9K

H-Index

24

Active since

2012

Affiliations

Bayer (Germany)(Current)

Heinrich Heine University Düsseldorf

Deutsches Diabetes-Zentrum e.V.

German Center for Diabetes Research

Steno Diabetes Centers

Markus F. Scheerer is an author at Bayer (Germany) specializing in medicine, pharmacology, and diabetes mellitus.

Publications per year

2012–2026

34

Publications

34

Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes

Rajiv Agarwal, Jennifer B. Green, Hiddo J.L. Heerspink et al. · New England Journal of Medicine · 2025 · 217 citations · Full text

, , +17

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos et al. · Diabetes Care · 2022 · 199 citations · Full text

, , +17

Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy

Peter Rossing, Gerasimos Filippatos, Rajiv Agarwal et al. · Kidney International Reports · 2021 · 165 citations · Full text

, , +17

SGLT-2 Inhibitors and Cardiovascular Risk

Matthew A. Cavender, Anna Norhammar, Kåre I. Birkeland et al. · Journal of the American College of Cardiology · 2018 · 129 citations · Full text

, , +17

Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials

Per‐Henrik Groop, Paresh Dandona, Moshe Phillip et al. · The Lancet Diabetes & Endocrinology · 2020 · 78 citations

, , +6

1–5 of 34